


L2

STR



VAR G1=C/O

REP G2=(1-2) A

VAR G3=S/C

VAR G4=11/10/12

NODE ATTRIBUTES:

NSPEC IS R AT 27

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 15 7 17

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

=> d his 13

(FILE 'REGISTRY' ENTERED AT 08:20:30 ON 22 JUL 2009)


L3 2326 SEA FILE=REGISTRY SSS FUL L2

=> d 14

L4 HAS NO ANSWERS

L4

STR



```

VAR G1=C/O
REP G2=(1-2) A
VAR G3=S/C
VAR G4=11/10/12
NODE ATTRIBUTES:
NSPEC   IS R       AT 27
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RSPEC 15 7 17
NUMBER OF NODES IS 27

```

STEREO ATTRIBUTES: NONE

=> d his 15

```

(FILE 'REGISTRY' ENTERED AT 08:20:30 ON 22 JUL 2009)
L5          110 SEARCH L4 SSS SUB=L3 FUL

```

=> d his 16

```


(FILE 'CAPLUS' ENTERED AT 08:22:06 ON 22 JUL 2009)
L6          17 S L5

```

```

=> d 17
L7 HAS NO ANSWERS
L7          STR

```



```

VAR G1=C/O
REP G2=(1-2) A
VAR G3=S/C
VAR G4=11/10/12
NODE ATTRIBUTES:
NSPEC   IS R       AT 27
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RSPEC 15 7 17

```

NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

=> d his 18

(FILE 'REGISTRY' ENTERED AT 08:26:47 ON 22 JUL 2009)
L8 269 SEARCH L7 SSS SUB=L3 FUL

=> d his 19

(FILE 'CAPLUS' ENTERED AT 08:29:06 ON 22 JUL 2009)
L9 82 S L8

=> d his 112

(FILE 'CAPLUS' ENTERED AT 08:32:39 ON 22 JUL 2009)
FILE 'REGISTRY' ENTERED AT 08:32:55 ON 22 JUL 2009
FILE 'CAPLUS' ENTERED AT 08:32:57 ON 22 JUL 2009
FILE 'CAPLUS' ENTERED AT 08:33:10 ON 22 JUL 2009
L12 4 S L6 AND L9

L12

4 L6 AND L9

=> d bib hitstr 1-4

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:652149 CAPLUS

DN 147:268307

TI Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

AU Richardson, Timothy I.; Frank, Scott A.; Wang, Minmin; Clarke, Christian A.; Jones, Scott A.; Ying, Bai-Ping; Kohlman, Dan T.; Wallace, Owen B.; Shepherd, Timothy A.; Dally, Robert D.; Palkowitz, Alan D.; Geiser, Andrew G.; Bryant, Henry U.; Henck, Judith W.; Cohen, Ilene R.; Rudmann, Daniel G.; McCann, Denis J.; Coutant, David E.; Oldham, Samuel W.; Hummel, Conrad W.; Fong, Kin C.; Hinklin, Ronald; Lewis, George; Tian, Hongqi; Dodge, Jeffrey A.

CS Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA

SO Bioorganic & Medicinal Chemistry Letters (2007), 17(13), 3544-3549
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 147:268307

IT 648904-56-7P 648904-79-4P 648905-29-7P

648906-06-3P 648906-10-9P 770708-13-9P

862129-77-9P 862129-80-4P 862129-85-9P


862129-87-1P 862130-04-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety)


RN 648904-56-7 CAPLUS

CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 648904-79-4 CAPLUS

CN 2-Naphthalenol, 6-[4-(ethylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 648905-29-7 CAPLUS

CN 2-Naphthalenol, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 648906-06-3 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[4-(ethylsulfonyl)phenyl]-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 648906-10-9 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[4-(methylsulfonyl)phenyl]-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 770708-13-9 CAPLUS


CN Benzenesulfonamide, 4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-naphthalenyl]-N,N-dimethyl- (CA INDEX NAME)



RN 862129-77-9 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 862129-80-4 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methylsulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862129-85-9 CAPLUS
 CN 2-Naphthalenol, 6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 862129-87-1 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl


RN 862130-04-9 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyloxy)phenoxy]-6-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)- (CA INDEX NAME)




IT 648906-05-2 648906-08-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Structure-activity relationships of SERMs optimized for uterine
 antagonism and ovarian safety)
 RN 648906-05-2 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-[4-(ethylsulfonyl)phenyl]-6-(
 (phenylmethoxy)benzo[b]thien-3-yl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




RN 648906-08-5 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-[4-(methylsulfonyl)phenyl]-6-(
 (phenylmethoxy)benzo[b]thien-3-yl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




IT 648904-52-3P 648904-77-2P 648905-66-2P
 862129-75-7P 862129-82-6P 946077-38-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Structure-activity relationships of SERMs optimized for uterine
 antagonism and ovarian safety)
 RN 648904-52-3 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)phenyl]-1-
 naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




RN 648904-77-2 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-[4-(ethylsulfonyl)phenyl]-6-methoxy-1-
 naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)



RN 648905-66-2 CAPLUS
 CN Benzenesulfonamide, 4-[6-methoxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-naphthalenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 862129-75-7 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)



RN 862129-82-6 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-6-methoxy-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

//
O

RN 946077-38-9 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-[(1-methylethyl)sulfonyl]phenyl]-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




IT 862130-05-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety)
 RN 862130-05-0 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methylsulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:732632 CAPLUS
DN 143:211843
TI Preparation of piperidine derivatives as selective estrogen receptor
modulators for treating endometriosis and uterine leiomyoma
IN Dodge, Jeffrey Alan; Frank, Scott Alan; Hummel, Conrad Wilson
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005073206	A1	20050811	WO 2005-US22	20050118
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1709023	A1	20061011	EP 2005-704876	20050118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	US 20070066595	A1	20070322	US 2006-597117	20060712
PRAI	US 2004-538303P	P	20040122		
	WO 2005-US22	W	20050118		
OS	CASREACT 143:211843; MARPAT 143:211843				
IT	862129-94-0P, 1-[2-[4-[[6-Benzoyloxy-2-(4-methylsulfonylcyclohex-1-enyl)naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine				
	RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)				
	(chromatog. resolution; preparation of piperidine derivs. as selective estrogen				
	receptor modulators for treating endometriosis and uterine leiomyoma)				
RN	862129-94-0 CAPLUS				
CN	Piperidine, 1-[2-[4-[[2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-6-(phenylmethoxy)-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)				




IT 862129-74-6P, 1-[2-[4-[[2-(4-Methylsulfonylcyclohex-1-enyl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine Hydrochloride
 862129-75-7P, 1-[2-[4-[[2-(4-Methylsulfonylcyclohex-1-enyl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 862129-77-9P
 , 6-(4-Methylsulfonylcyclohex-1-enyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 862129-82-6P,
 1-[2-[4-[[2-(1,1-Dioxo-1,2,3,6-tetrahydrothiopyran-4-yl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 862129-84-8P
 , 1-[2-[4-[[2-(1,1-Dioxo-1,2,3,6-tetrahydrothiopyran-4-yl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine hydrochloride
 862129-85-9P, 6-(1,1-Dioxo-1,2,3,6-tetrahydrothiopyran-4-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 862129-86-0P,
 6-(1,1-Dioxo-1,2,3,6-tetrahydrothiopyran-4-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 862129-89-3P,
 1-[2-[4-[[6-Methoxy-2-(tetrahydrothiopyran-4-yl)benzo[b]thiophen-3-yl]oxy]phenoxy]ethyl]piperidine 862129-90-6P,
 3-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-2-(tetrahydrothiopyran-4-yl)benzo[b]thiophen-6-ol 862130-03-8P,
 2-(4-Methylsulfonylcyclohex-1-enyl)-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of piperidine derivs. as selective estrogen receptor modulators for treating endometriosis and uterine leiomyoma)


RN 862129-74-6 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-1-naphthalenyl]oxy]phenoxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862129-75-7 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




RN 862129-77-9 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 862129-82-6 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-6-methoxy-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

//
O

RN 862129-84-8 CAPLUS
 CN Piperidine, 1-[2-[4-[[2-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-6-methoxy-1-naphthalenyl]oxy]phenoxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 862129-85-9 CAPLUS
 CN 2-Naphthalenol, 6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 862129-86-0 CAPLUS
CN 2-Naphthalenol, 6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862129-89-3 CAPLUS
 CN Piperidine, 1-[2-[4-[[6-methoxy-2-(tetrahydro-2H-thiopyran-4-yl)benzo[b]thien-3-yl]oxy]phenoxy]ethyl]- (CA INDEX NAME)




RN 862129-90-6 CAPLUS
 CN Benzo[b]thiophene-6-ol, 3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(tetrahydro-2H-thiopyran-4-yl)- (CA INDEX NAME)



RN 862130-03-8 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[4-(methanesulfonyl)-1-cyclohexen-1-yl]-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




IT 862129-76-8P, 6-(4-Methanesulfonylcyclohex-1-enyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride
 862129-78-0P, 6-cis-(4-Methanesulfonylcyclohexyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride
 862129-79-1P, 6-trans-(4-Methanesulfonylcyclohexyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride
 862129-80-4P, 6-(4-Methanesulfonylcyclohexyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 862129-87-1P,
 6-(1,1-Dioxohexahydrothiopyran-4-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol Hydrochloride 862129-91-7P,
 2-(1,1-Dioxohexahydrothiopyran-4-yl)-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol hydrochloride 862129-92-8P
 , 6-((S)-4-Methanesulfonylcyclohex-1-enyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 862129-93-9P,
 6-((R)-4-Methanesulfonylcyclohex-1-enyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 862130-00-5P,
 2-(4-Methanesulfonylcyclohex-1-enyl)-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol hydrochloride 862130-04-9P
 , 6-(1,1-Dioxohexahydrothiopyran-4-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 862130-05-0P,
 6-(4-Methanesulfonylcyclohexyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 862130-06-1P,
 3-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-2-(tetrahydrothiopyran-4-yl)benzo[b]thiophen-6-ol hydrochloride 862130-07-2P,
 2-(1,1-Dioxohexahydrothiopyran-4-yl)-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidine derivs. as selective estrogen receptor modulators for treating endometriosis and uterine leiomyoma)


RN 862129-76-8 CAPLUS

CN 2-Naphthalenol, 6-[4-(methanesulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)




RN 862129-78-0 CAPLUS
 CN 2-Naphthalenol, 6-[cis-4-(methanesulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




RN 862129-79-1 CAPLUS
 CN 2-Naphthalenol, 6-[trans-4-(methanesulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 862129-80-4 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methanesulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862129-87-1 CAPLUS
 CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 862129-91-7 CAPLUS
CN Benzo[b]thiophene-6-ol, 3-[4-[2-(1-piperidinyloxy)phenoxy]-2-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 862129-92-8 CAPLUS

CN 2-Naphthalenol, 6-[(4S)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 862129-93-9 CAPLUS

CN 2-Naphthalenol, 6-[(4R)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 862130-00-5 CAPLUS


CN Benzo[b]thiophene-6-ol, 2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862130-04-9 CAPLUS
 CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

//
O

RN 862130-05-0 CAPLUS
 CN 2-Naphthalenol, 6-[4-(methylsulfonyl)cyclohexyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)




RN 862130-06-1 CAPLUS
 CN Benzo[b]thiophene-6-ol, 3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(tetrahydro-2H-thiopyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862130-07-2 CAPLUS
 CN Benzo[b]thiophene-6-ol, 3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)- (CA INDEX NAME)



IT 862129-95-1P, 1-[2-[4-[[6-Benzyloxy-2-(S)-4-


methylsulfonylcyclohex-1-enyl)naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine
 862129-96-2P, 1-[2-[4-[[6-Benzyloxy-2-((R)-4-
 methylsulfonylcyclohex-1-enyl)naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic
 preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidine derivs. as selective estrogen receptor modulators
 for treating endometriosis and uterine leiomyoma)

RN 862129-95-1 CAPLUS

CN Piperidine, 1-[2-[4-[[2-[(4S)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-6-
 (phenylmethoxy)-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862129-96-2 CAPLUS

CN Piperidine, 1-[2-[4-[[2-[(4R)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-6-
 (phenylmethoxy)-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 862129-83-7P, 1-[2-[4-[[2-(3,6-Dihydro-2H-thiopyran-4-yl)-6-
 methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 862129-88-2P
 , 4-[6-Methoxy-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-2-
 yl]tetrahydrothiopyran-4-ol 862129-97-3P,
 1-[2-[4-[[6-Benzyloxy-2-((S)-4-methylsulfonylcyclohex-1-enyl)naphthalen-1-
 yl]oxy]phenoxy]ethyl]piperidine hydrochloride 862129-98-4P,
 6-((S)-4-Methylsulfonylcyclohex-1-enyl)-5-[4-[2-(piperidin-1-
 yl)ethoxy]phenoxy]naphthalen-2-ol 862129-99-5P,
 1-[2-[4-[[6-Benzyloxy-2-((R)-4-methylsulfonylcyclohex-1-enyl)naphthalen-1-
 yl]oxy]phenoxy]ethyl]piperidine hydrochloride 862130-01-6P,
 1-[2-[4-[[2-(4-Methylsulfonylcyclohex-1-enyl)-6-methoxybenzo[b]thiophen-3-
 yl]oxy]phenoxy]ethyl]piperidine 862130-02-7P,
 1-[2-[4-[[2-(4-Methylsulfonylcyclohex-1-enyl)-6-methoxybenzo[b]thiophen-3-
 yl]oxy]phenoxy]ethyl]piperidine hydrochloride
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of piperidine derivs. as selective estrogen receptor modulators
for treating endometriosis and uterine leiomyoma)


RN 862129-83-7 CAPLUS

CN Piperidine, 1-[2-[4-[[2-(3,6-dihydro-2H-thiopyran-4-yl)-6-methoxy-1-naphthalenyl]oxy]phenoxy]ethyl]- (CA INDEX NAME)



RN 862129-88-2 CAPLUS


CN 2H-Thiopyran-4-ol, tetrahydro-4-[6-methoxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thien-2-yl]- (CA INDEX NAME)



RN 862129-97-3 CAPLUS

CN Piperidine, 1-[2-[4-[[2-[(4S)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-6-(phenylmethoxy)-1-naphthalenyl]oxy]phenoxy]ethyl]-, hydrochloride (1:1)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 862129-98-4 CAPLUS

CN 2-Naphthalenol, 6-[(4S)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862129-99-5 CAPLUS

CN Piperidine, 1-[2-[4-[[2-[(4R)-4-(methylsulfonyl)-1-cyclohexen-1-yl]-6-(phenylmethoxy)-1-naphthalenyl]oxy]phenoxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 862130-01-6 CAPLUS

CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]benzo[b]thien-3-yl]oxy]phenoxy]ethyl]- (CA INDEX NAME)



RN 862130-02-7 CAPLUS

CN Piperidine, 1-[2-[4-[[6-methoxy-2-[4-(methylsulfonyl)-1-cyclohexen-1-yl]benzo[b]thien-3-yl]oxy]phenoxy]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1997:80141 CAPLUS

DN 126:74703

OREF 126:14457a,14460a

TI Structure-Activity Relationships of Selective Estrogen Receptor
Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene

AU Grese, Timothy A.; Cho, Stephen; Finley, Don R.; Godfrey, Alexander G.;
Jones, Charles D.; Lugar, Charles W., III; Martin, Michael J.; Matsumoto,
Ken; Pennington, Lewis D.; et al.

CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN,
46285, USA

SO Journal of Medicinal Chemistry (1997), 40(2), 146-167

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 150797-71-0P 174475-56-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)

(preparation of arylbenzothiophenes as estrogen receptor modulators)

RN 150797-71-0 CAPLUS


CN Methanone, (2-cyclohexyl-6-hydroxybenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 174475-56-0 CAPLUS

CN Methanone, [6-hydroxy-2-(trans-4-hydroxycyclohexyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 150797-34-5P 174475-53-7P 185415-02-5P


185416-86-8P 185416-87-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylbenzothiophenes as estrogen receptor modulators)

RN 150797-34-5 CAPLUS


CN Methanone, (2-cyclohexyl-6-methoxybenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 174475-53-7 CAPLUS

CN Methanone, [2-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 185415-02-5 CAPLUS
 CN Methanone, [2-(4-fluorophenyl)-6-[(methanesulfonyl)oxy]benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 185416-86-8 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-, 2-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thiophen-6-yl ester (CA INDEX NAME)




RN 185416-87-9 CAPLUS
 CN Methanesulfonic acid, 1,1,1-trifluoro-, 4-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl ester (CA INDEX NAME)



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1995:758723 CAPLUS
DN 123:143630
OREF 123:25577a,25580a
TI Benzothiophenes and related compounds as estrogen agonists
IN Cameron, Kimberly O.; Da Silva-Jardine, Paul; Larson, Eric R.; Hauske, James R.; Rosati, Robert L.
PA Pfizer Inc., USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9510513	A1	19950420	WO 1994-IB282	19940919
	W: AU, BR, CA, CN, CZ, HU, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2173243	A1	19950420	CA 1994-2173243	19940919
	AU 9475453	A	19950504	AU 1994-75453	19940919
	EP 723537	A1	19960731	EP 1994-925597	19940919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1133040	A	19961009	CN 1994-193755	19940919
	JP 08511273	T	19961126	JP 1994-511552	19940919
	BR 9407790	A	19970318	BR 1994-7790	19940919
	HU 75231	A2	19970428	HU 1996-947	19940919
	FI 9404771	A	19950413	FI 1994-4771	19941011
	ZA 9407911	A	19960411	ZA 1994-7911	19941011
	NO 9601432	A	19960411	NO 1996-1432	19960411
	US 6756388	B1	20040629	US 1996-628605	19960701
PRAI	US 1993-135386	A	19931012		
	WO 1994-IB282	W	19940919		
OS	CASREACT 123:143630; MARPAT 123:143630				
IT	166975-48-0P 166975-49-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of benzothiophene derivs. and analogs as estrogen agonists)				
RN	166975-48-0 CAPLUS				
CN	Methanone, [4-[2-(2-azabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl][6-[(methylsulfonyl)oxy]-2-[4-[(methylsulfonyl)oxy]phenyl]benzo[b]thien-3-yl]-				
	(CA INDEX NAME)				



RN 166975-49-1 CAPLUS

CN Methanone, [4-[2-(1H-imidazol-1-yl)ethoxy]phenyl][6-[(methanesulfonyl)oxy]-2-[4-[(methanesulfonyl)oxy]phenyl]benzo[b]thien-3-yl]- (CA INDEX NAME)




IT 150797-71-0P 166975-22-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiophene derivs. and analogs as estrogen agonists)


RN 150797-71-0 CAPLUS

CN Methanone, (2-cyclohexyl-6-hydroxybenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 166975-22-0 CAPLUS

CN Methanesulfonamide, N-[2-(4-hydroxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-6-yl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT